Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 4

4(57.1%)

Early Phase 1

1(14.3%)

N/A

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 4(4)

Early Phase 1(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02192931Phase 4Completed

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

Role: lead

NCT02134808Phase 4Completed

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Role: lead

NCT02356107Phase 4Completed

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

Role: lead

NCT01601210Early Phase 1Completed

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Role: lead

NCT02189915Not ApplicableTerminated

Open-Label Creatine Study for Female Meth Users

Role: lead

NCT01514630Phase 4Completed

Creatine as a Treatment Option for Depression in Methamphetamine Using Females

Role: lead

NCT00950352Phase 3Completed

Citicoline Treatment of Methamphetamine Dependence

Role: lead

All 7 trials loaded